$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Targeted Oncology10h
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Cure Today12h
An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
The Scientist9h
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows
In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.
PipelineReview.com18h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...